United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 24/06/2025 BST			5-day change	1st Jan Change
289.94 ^USD	+1.24%		+1.07%	-17.83%

06-24	United Therapeutics Corporation and Intermountain Health Announce the First Patient Treated with External Liver Support Using a Bioengineered Liver	CI
06-23	Liquidia Gets $50 Million From Healthcare Royalty	MT

Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M

Published on 01/05/2024 at 11:37, updated on 01/05/2024 at 11:38

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about United Therapeutics Corporation

United Therapeutics Corporation and Intermountain Health Announce the First Patient Treated with External Liver Support Using a Bioengineered Liver	06-24	CI
Liquidia Gets $50 Million From Healthcare Royalty	06-23	MT
United Therapeutics Corporation Concludes Enrollment of the Advance Outcomes Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension	06-23	CI
United Therapeutics delivers 18th consecutive quarter of topline growth	06-17
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing	06-16	MT
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	06-10	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	06-10	MT
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension	06-02	MT
Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	06-02	MT
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension	05-23	MT
Liquidia Faces Patent Litigation Filed by United Therapeutics	05-12	MT
Liquidia Says New Litigation Filed Against Co In U.S.	05-12	RE
United Therapeutics Corporation, Q1 2025 Earnings Call, Apr 30, 2025	04-30
United Therapeutics Q1 Earnings, Revenue Rise	04-30	MT
Earnings Flash (UTHR) United Therapeutics Posts Q1 Revenue $794.4M, vs. FactSet Est of $729.3M	04-30	MT
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	04-30	CI
United Therapeutics Enters Credit Agreement With Wells Fargo - SEC Filing	04-28	RE
United Therapeutics Corporation Announces Credit Agreement Established for A $2.5 Billion Revolving Facility	04-28	CI
Liquidia Corp Unit Files Patent Infringement Action Against United Therapeutics	04-22	RE
BofA Securities Upgrades United Therapeutics to Neutral From Underperform	04-21	MT
United Therapeutics Insider Sold Shares Worth $3,121,543, According to a Recent SEC Filing	04-21	MT
United Therapeutics Insider Sold Shares Worth $1,138,200, According to a Recent SEC Filing	04-08	MT
United Therapeutics Insider Sold Shares Worth $3,367,984, According to a Recent SEC Filing	04-07	MT
United Therapeutics Insider Sold Shares Worth $796,991, According to a Recent SEC Filing	03-25	MT

Chart United Therapeutics Corporation

Duration

Period

UTHR: Dynamic Chart

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Employees

1,305

Sector

Pharmaceuticals

Calendar

06-26 - Annual General Meeting

More about the company